Source: Pharmacy Times articles
This new generic will impact both oncology and community pharmacists.
Read More
Recent Content
- CX-2051 Proves Safe and Effective in Advanced Colon Cancer
- CVS Health Announces It Will Drop Zepbound and Prioritize Coverage of Wegovy
- Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
- Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma
- Zepbound Shows Superior Weight Loss Compared to Wegovy in SURMOUNT-5 Trial
- New OTC Option Offers Patients Itch Relief During Summer Activities
- FDA Approves Emrelis in Previously Treated, Advanced NSCLC
- FDA Grants Accelerated Approval to Telisotuzumab vedotin-tllv for NSCLC
- Survivors of Breast Cancer May Still Struggle with Fear of Recurrence
- FDA Approves Welireg for Pheochromocytoma and Paraganglioma